{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:53:37Z","timestamp":1776423217106,"version":"3.51.2"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T00:00:00Z","timestamp":1363651200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00702-013-1001-5","type":"journal-article","created":{"date-parts":[[2013,3,18]],"date-time":"2013-03-18T13:59:20Z","timestamp":1363615160000},"page":"1321-1329","source":"Crossref","is-referenced-by-count":32,"title":["The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson\u2019s disease"],"prefix":"10.1007","volume":"120","author":[{"given":"Nir","family":"Giladi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak","family":"Boroojerdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwin","family":"Surmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,19]]},"reference":[{"key":"1001_CR1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.parkreldis.2012.01.008","volume":"18","author":"LW Elmer","year":"2012","unstructured":"Elmer LW, Surmann E, Boroojerdi B, Jankovic J (2012) Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson\u2019s disease: a prospective, open-label extension study. Parkinsonism Relat Disord 18:488\u2013493. doi: 10.1016\/j.parkreldis.2012.01.008","journal-title":"Parkinsonism Relat Disord"},{"key":"1001_CR2","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.clinthera.2012.02.008","volume":"34","author":"JP Elshoff","year":"2012","unstructured":"Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W (2012) Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 34:966\u2013978. doi: 10.1016\/j.clinthera.2012.02.008","journal-title":"Clin Ther"},{"key":"1001_CR3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.nurt.2007.12.001","volume":"5","author":"SA Factor","year":"2008","unstructured":"Factor SA (2008) Current status of symptomatic medical therapy in Parkinson\u2019s disease. Neurotherapeutics 5:164\u2013180","journal-title":"Neurotherapeutics"},{"key":"1001_CR4","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/mds.21741","volume":"22","author":"N Giladi","year":"2007","unstructured":"Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH (2007) Rotigotine transdermal patch in early Parkinson\u2019s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22:2398\u20132404","journal-title":"Mov Disord"},{"key":"1001_CR5","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00702-010-0506-4","volume":"117","author":"N Giladi","year":"2010","unstructured":"Giladi N, Fichtner A, Poewe W, Boroojerdi B (2010) Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson\u2019s disease. J Neural Transm 117:1395\u20131399","journal-title":"J Neural Transm"},{"key":"1001_CR6","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/mds.21743","volume":"22","author":"RA Hauser","year":"2007","unstructured":"Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE (2007) Ten-year follow-up of Parkinson\u2019s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22:2409\u20132417","journal-title":"Mov Disord"},{"key":"1001_CR7","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archneur.61.7.1044","volume":"61","author":"RG Holloway","year":"2004","unstructured":"Holloway RG, Shoulson I, Fahn S et al (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044\u20131053","journal-title":"Arch Neurol"},{"issue":"Suppl 11","key":"1001_CR8","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","volume":"20","author":"J Jankovic","year":"2005","unstructured":"Jankovic J (2005) Motor fluctuations and dyskinesias in Parkinson\u2019s disease: clinical manifestations. Mov Disord 20(Suppl 11):S11\u2013S16","journal-title":"Mov Disord"},{"key":"1001_CR9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/NDT.S2006","volume":"4","author":"J Jankovic","year":"2008","unstructured":"Jankovic J, Aguilar LG (2008) Current approaches to the treatment of Parkinson\u2019s disease. Neuropsychiatr Dis Treat 4:743\u2013757","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1001_CR10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/archneur.64.5.676","volume":"64","author":"J Jankovic","year":"2007","unstructured":"Jankovic J, Watts RL, Martin W, Boroojerdi B (2007) Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 64:676\u2013682","journal-title":"Arch Neurol"},{"key":"1001_CR11","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","volume":"68","author":"PA LeWitt","year":"2007","unstructured":"LeWitt PA, Lyons KE, Pahwa R (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68:1262\u20131267","journal-title":"Neurology"},{"key":"1001_CR12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/archneurol.2009.32","volume":"66","author":"Parkinson Study Group","year":"2009","unstructured":"Parkinson Study Group (2009) Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 66:563\u2013570","journal-title":"Arch Neurol"},{"issue":"Suppl 7","key":"1001_CR13","doi-asserted-by":"crossref","first-page":"VII2","DOI":"10.1007\/s00415-006-7002-7","volume":"253","author":"W Poewe","year":"2006","unstructured":"Poewe W (2006) The natural history of Parkinson\u2019s disease. J Neurol 253(Suppl 7):VII2\u2013VII6","journal-title":"J Neurol"},{"key":"1001_CR14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","volume":"6","author":"WH Poewe","year":"2007","unstructured":"Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6:513\u2013520","journal-title":"Lancet Neurol"},{"key":"1001_CR15","first-page":"229","volume":"5","author":"W Poewe","year":"2010","unstructured":"Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F (2010) Levodopa in the treatment of Parkinson\u2019s disease: an old drug still going strong. Clin Interv Aging 5:229\u2013238","journal-title":"Clin Interv Aging"},{"key":"1001_CR16","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484\u20131491","journal-title":"N Engl J Med"},{"key":"1001_CR17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00210-008-0341-4","volume":"379","author":"D Scheller","year":"2009","unstructured":"Scheller D, Ullmer C, Berkels R, Gwarek M, L\u00fcbbert H (2009) The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol 379:73\u201386","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1001_CR18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M et al (2011) Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26:90\u201399","journal-title":"Mov Disord"},{"key":"1001_CR19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","volume":"68","author":"RL Watts","year":"2007","unstructured":"Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J (2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68:272\u2013276","journal-title":"Neurology"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-1001-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-013-1001-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-1001-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:30:23Z","timestamp":1559104223000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-013-1001-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,19]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1007\/s00702-013-1001-5","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,19]]}}}